QuickView for TFS-II;jsessionid=FD9D07EA4FEA2E9D62FC365AA7DE59D3;jsessionid=86A2AA8A39E51C0F450049D37E597C04;jsessionid=C1188DFB6C25D0C9A6AAC30CD302840A;jsessionid=56D31E8168613DBD0D91D69AD7C1ED23;jsessionid=3EB46B0E247396864BA931797642C732;jsessionid=5A559DE54109719F59C6321DD18E43BF;jsessionid=168D1043C48148D18F724CFB4672BDAA;jsessionid=80FA799B5E2BF6DDC207039A9CAFA693;jsessionid=46BA4C7069E2B58C1981F20A38C42326 (gene)

1. Thymic stroma and TFII-I: towards new targeted therapies.
2. Proteomic analysis of SRF associated transcription complexes identified TFII-I as modulator of SRF f…
3. Structural basis for evolutionarily conserved interactions between TFIIS and Paf1C.
4. The TFIIS N-terminal domain (TND): a transcription assembly module at the interface of order and dis…
5. Astragaloside IV attenuates sunitinib-associated cardiotoxicity by inhibiting COUP-TFII.

There were no clinical trials for TFS-II;jsessionid=FD9D07EA4FEA2E9D62FC365AA7DE59D3;jsessionid=86A2AA8A39E51C0F450049D37E597C04;jsessionid=C1188DFB6C25D0C9A6AAC30CD302840A;jsessionid=56D31E8168613DBD0D91D69AD7C1ED23;jsessionid=3EB46B0E247396864BA931797642C732;jsessionid=5A559DE54109719F59C6321DD18E43BF;jsessionid=168D1043C48148D18F724CFB4672BDAA;jsessionid=80FA799B5E2BF6DDC207039A9CAFA693;jsessionid=46BA4C7069E2B58C1981F20A38C42326